SAN FRANCISCO, Nov. 17, 2010 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA), a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today announced that Barry M. Sherman, M.D., has been elected to Jennerex's board of directors.
"Dr. Sherman's extensive biopharmaceutical leadership experience, coupled with his broad knowledge of cancer therapeutics research and development, will be extremely valuable to Jennerex as we proceed toward commercialization of our lead product JX-594," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "While chief medical officer at Genentech, Dr Sherman was instrumental in bringing their major products to the market including multiple major oncology products from the monoclonal antibody therapeutic class. We look forward to his strategic and operational guidance as we advance products from our pipeline through clinical trials and to the market."
Dr. Sherman has more than 30 years of experience in academic and pharmaceutical biomedical research and development, including his tenure as Genentech's first senior vice president and chief medical officer. Most recently, he was executive vice president and co-founder of BiPar Sciences where he led the development of the Company's lead product until its acquisition by Sanofi Aventis. He has served as president and chief executive officer of Anergen Inc., and was a founder of Pain Therapeutics, Inc. Prior to joining Genentech in 1985, Dr. Sherman was professor of medicine and endocrinology at the University of Iowa-College of Medicine, where he served as associate chairman of the department of internal medicine and director of the National Institutes of Health-sponsored Clinical Research Center.
Dr. Sherman is a graduate of the University of Michigan in Ann Arbor, where he received both his A.B. and M.D. degrees with honors. He completed his clinical and research training at the Albert Einstein College of Medicine in New York, the NIH in Bethesda, Maryland, and the University of Michigan. He has contributed more than 125 publications to the scientific literature, including articles, chapters and books resulting from his NIH-funded laboratory and human investigation, and results from the study of new pharmaceuticals.
Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.
SOURCE Jennerex, Inc.